Evidence map›Paper›PMID 33942202›Full record

ArticleInvestigational new drugs2021

Identification of CDC20 as an immune infiltration-correlated prognostic biomarker in hepatocellular carcinoma.

Chen Xiong, Zhihuai Wang, Guifu Wang, Chi Zhang, Shengjie Jin, Guoqing Jiang, Dousheng Bai

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The High-Affinity IL-2 Receptor Affects White Matter Damage after Cerebral Ischemia by Regulating CD8 + T Lymphocyte Differentiation.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. CDC20: a novel therapeutic target in cancer.American journal of translational research · 2023
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Chen Xiong *Dalian Medical University, 116044, Dalian, Liaoning, China.
Zhihuai Wang *Dalian Medical University, 116044, Dalian, Liaoning, China.
Guifu WangDalian Medical University, 116044, Dalian, Liaoning, China.
Chi ZhangDepartment of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, 98 West Nantong Rd, 225009, Yangzhou, Jiangsu, China.
Shengjie JinDepartment of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, 98 West Nantong Rd, 225009, Yangzhou, Jiangsu, China.
Guoqing JiangDepartment of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, 98 West Nantong Rd, 225009, Yangzhou, Jiangsu, China.
Dousheng BaiDepartment of Hepatobiliary Surgery, Clinical Medical College, Yangzhou University, 98 West Nantong Rd, 225009, Yangzhou, Jiangsu, China. drbaidousheng@163.com.ORCID http://orcid.org/0000-0001-8032-7959
Yangzhou University · CNDalian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is a malignancy with a poor prognosis. E3 ubiquitin-protein ligases play essential roles in HCC, such as regulating progression, migration, and metastasis. We aimed to explore a hub E3 ubiquitin-protein ligase gene and verify its association with prognosis and immune cell infiltration in HCC. Cell division cycle 20 (CDC20) was identified as a hub E3 ubiquitin-protein ligase in HCC by determining the intersecting genes in a protein-protein interaction (PPI) network of differentially expressed genes (DEGs) using HCC data from the International Cancer Genome Consortium (ICGC) and the gene list of 919 E3 ubiquitin-protein ligases. DEGs and their correlations with clinicopathological features were explored in The Cancer Genome Atlas (TCGA), ICGC, and Gene Expression Omnibus (GEO) databases via the Wilcoxon signed-rank test. The prognostic value of CDC20 was illustrated by Kaplan-Meier (K-M) curves and Cox regression analyses. Subsequently, the correlation between CDC20 and immune infiltration was demonstrated via the Tumor Immune Estimation Resource (TIMER) and Gene Expression Profiling Interactive Analysis (GEPIA). CDC20 expression was significantly higher in HCC than in normal tissues (all P < 0.05). High CDC20 expression predicted a poor prognosis and might be an independent risk factor in HCC (P < 0.05). Additionally, CDC20 was correlated with the immune infiltration of CD8 + T cells, T cells (general), monocytes, and exhausted T cells. This study reveals the potential prognostic value of CDC20 in HCC and demonstrates that CDC20 may be an immune-associated therapeutic target in HCC because of its correlation with immune infiltration.

Indexed as

Biomarkers, TumorCarcinoma, HepatocellularCdc20 ProteinsDatabases, GeneticGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateLiver NeoplasmsPrognosisProtein Interaction MapsUbiquitin-Protein LigasesBiomarkers, TumorCDC20 protein, humanCdc20 ProteinsUbiquitin-Protein LigasesCDC20E3 ubiquitin-protein ligasehepatocellular carcinomaimmune infiltrationprognosis

Identifiers

PMID33942202
OpenAlexW3156832669

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.